MCID: DRM010
MIFTS: 61

Dermatomyositis

Categories: Bone diseases, Immune diseases, Muscle diseases, Nephrological diseases, Neuronal diseases, Rare diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Dermatomyositis

MalaCards integrated aliases for Dermatomyositis:

Name: Dermatomyositis 11 19 52 58 75 53 43 14 16 71 33
Amyopathic Dermatomyositis 11 19 71
Adult Dermatomyositis 19 58
Dermatopolymyositis 11 31
Polymyositis with Skin Involvement 11
Adult Type Dermatomyositis 71
Petges-Clejat Syndrome 33

Characteristics:


Prevelance:

1-9/1000000 (Europe, Australia, Argentina, United States, Spain) 1-9/100000 (Europe, Australia) 1-5/10000 (Argentina) 58

Age Of Onset:

All ages 58

Classifications:

Orphanet: 58  
Rare neurological diseases
Rare renal diseases
Rare systemic and rhumatological diseases
Rare skin diseases


Summaries for Dermatomyositis

NINDS: 52 Dermatomyositis is one of a group of muscle diseases known as the inflammatory myopathies, which are characterized by chronic muscle inflammation accompanied by muscle weakness.  Dermatomyositis’ cardinal symptom is a skin rash that precedes, accompanies, or follows  progressive muscle weakness.  The rash looks patchy, with purple or red discolorations, and characteristically develops on the eyelids and on muscles used to extend or straighten joints, including knuckles, elbows, knees, and toes.  Red rashes may also occur on the face, neck, shoulders, upper chest, back, and other locations, and there may be swelling in the affected areas.  The rash sometimes occurs without obvious muscle involvement.  Adults with dermatomyositis may experience weight loss, a low-grade fever, inflamed lungs, and be sensitive to light such that the rash or muscle disease gets worse.  Children and adults with dermatomyositis may develop calcium deposits, which appear as hard bumps under the skin or in the muscle (called calcinosis).  Calcinosis most often occurs 1-3 years after the disease begins.  These deposits are seen more often in children with dermatomyositis than in adults.  In some cases of dermatomyositis, distal muscles (muscles located away from the trunk of the body, such as those in the forearms and around the ankles and wrists) may be affected as the disease progresses.  Dermatomyositis may be associated with collagen-vascular or autoimmune diseases, such as lupus.

MalaCards based summary: Dermatomyositis, also known as amyopathic dermatomyositis, is related to interstitial lung disease and inclusion body myositis, and has symptoms including pruritus and exanthema. An important gene associated with Dermatomyositis is RN7SL1 (RNA Component Of Signal Recognition Particle 7SL1), and among its related pathways/superpathways are miRNAs involvement in the immune response in sepsis and miRNAs involved in DNA damage response. The drugs Pirfenidone and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include muscle, skin where a skin rash is often seen prior to the onset of muscle weakness and skin, and related phenotypes are autoimmunity and emg abnormality

GARD: 19 Dermatomyositis is an autoimmune condition that causes skin changes and muscle weakness. Symptoms can include a red skin rash around the eyelids, red bumps around the joints, and muscle weakness in the arms and legs. Muscle weakness gets worse over time and can lead to stiff joints and muscle wasting. The cause for Dermatomyositis is unknown. Diagnosis is made through a clinical exam and microscopic examination of a piece of skin and muscle.

Orphanet: 58 A rare idiopathic inflammatory myopathy (IIM) characterized by evocative skin lesions, muscle involvement with symmetrical proximal muscle weakness, and specific histological features. The clinical subtypes are defined by the presence of myositis-specific antibodies (anti-Mi2, anti-NXP2, anti-TIF1-γ, anti-MDA5, or anti-SAE antibodies) and are associated with specific clinical phenotypes and prognosis.

Disease Ontology: 11 A myositis that results in inflammation located in muscle or located in skin where a skin rash is often seen prior to the onset of muscle weakness. The disease may result from either a viral infection or an autoimmune reaction.

Wikipedia: 75 Dermatomyositis (DM) is a long-term inflammatory disorder which affects skin and the muscles. Its... more...

Related Diseases for Dermatomyositis

Diseases in the Dermatomyositis family:

Adult Dermatomyositis

Diseases related to Dermatomyositis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1189)
# Related Disease Score Top Affiliating Genes
1 interstitial lung disease 31.8 MIR30A MIR223 MIR214 MIR21 MIR155
2 inclusion body myositis 31.3 MIR34A MIR223 MIR222 MIR221 MIR214 MIR21
3 polymyositis 31.0 RN7SL1 MIR362 MIR34A MIR30A MIR222 MIR221
4 skin disease 30.9 MIR34A MIR30A MIR223 MIR221 MIR21 MIR155
5 interstitial lung disease 2 30.7 MIR335 MIR30A MIR214 MIR21
6 melanoma 30.5 MIR34A MIR222 MIR221 MIR210 MIR21 MIR199B
7 nasopharyngeal carcinoma 30.4 MIR335 MIR30A MIR223 MIR214 MIR21 MIR155
8 thyroid cancer, nonmedullary, 1 30.3 MIR222 MIR221 MIR146B
9 rectum cancer 30.2 MIR30A MIR221 MIR214 MIR21
10 muscular disease 30.1 MIR335 MIR221 MIR21
11 diffuse large b-cell lymphoma 30.0 MIR222 MIR221 MIR214 MIR210 MIR21 MIR155
12 larynx cancer 30.0 MIR210 MIR21 MIR155 MIR148A
13 gallbladder disease 29.9 MIR30A MIR222 MIR214
14 demyelinating disease 29.9 MIR223 MIR21 MIR155 MIR132
15 non-alcoholic steatohepatitis 29.9 MIR34A MIR214 MIR21
16 kidney cancer 29.9 MIR30A MIR214 MIR210 MIR21
17 peripheral nervous system disease 29.9 MIR362 MIR34A MIR335 MIR30A MIR21 MIR132
18 ovarian cancer 29.8 MIR34A MIR335 MIR30A MIR223 MIR222 MIR221
19 thyroid gland cancer 29.8 MIR222 MIR221 MIR154 MIR146B
20 cervix carcinoma 29.8 MIR362 MIR30A MIR214 MIR21
21 follicular adenoma 29.8 MIR222 MIR221 MIR146B
22 papillary adenocarcinoma 29.8 MIR30A MIR221 MIR21
23 primary cutaneous t-cell non-hodgkin lymphoma 29.7 MIR34A MIR21 MIR155
24 non-alcoholic fatty liver disease 29.7 MIR34A MIR30A MIR21 MIR154 MIR132 MIR130A
25 immune deficiency disease 29.7 MIR34A MIR30A MIR223 MIR221 MIR210 MIR21
26 connective tissue disease 29.6 MIR362 MIR34A MIR335 MIR30A MIR223 MIR222
27 cervical cancer 29.6 MIR34A MIR30A MIR221 MIR214 MIR210 MIR21
28 bone disease 29.6 MIR34A MIR30A MIR223 MIR222 MIR221 MIR214
29 cerebrovascular disease 29.5 MIR335 MIR30A MIR223 MIR221 MIR210 MIR21
30 acute promyelocytic leukemia 29.5 MIR223 MIR221 MIR210 MIR154 MIR146B
31 leukemia, chronic lymphocytic 29.5 MIR34A MIR30A MIR223 MIR221 MIR214 MIR21
32 leukemia, acute lymphoblastic 29.4 MIR335 MIR223 MIR222 MIR221 MIR214 MIR210
33 retinal vascular disease 29.4 MIR335 MIR30A MIR223 MIR210 MIR21 MIR146B
34 lymphoma, non-hodgkin, familial 29.4 MIR34A MIR335 MIR30A MIR223 MIR222 MIR214
35 esophageal cancer 29.3 MIR34A MIR30A MIR299 MIR223 MIR222 MIR221
36 head and neck cancer 29.3 MIR34A MIR335 MIR30A MIR222 MIR221 MIR210
37 myocardial infarction 29.2 MIR34A MIR30A MIR223 MIR210 MIR21 MIR155
38 pancreatic cancer 29.2 MIR34A MIR30A MIR223 MIR222 MIR221 MIR214
39 prostate cancer 29.1 MIR34A MIR335 MIR30A MIR223 MIR222 MIR221
40 breast cancer 29.1 MIR34A MIR335 MIR30A MIR222 MIR221 MIR214
41 esophageal disease 29.1 MIR34A MIR30A MIR223 MIR222 MIR221 MIR214
42 lymphatic system disease 29.0 MIR34A MIR335 MIR30A MIR223 MIR222 MIR221
43 hematologic cancer 29.0 MIR34A MIR335 MIR30A MIR223 MIR222 MIR221
44 alzheimer disease, familial, 1 29.0 MIR34A MIR335 MIR30A MIR223 MIR210 MIR21
45 cardiovascular system disease 28.9 MIR34A MIR335 MIR30A MIR223 MIR222 MIR221
46 leukemia, acute myeloid 28.9 MIR362 MIR34A MIR335 MIR30A MIR223 MIR222
47 eye disease 28.8 MIR34A MIR335 MIR30A MIR223 MIR221 MIR214
48 ovarian disease 28.8 MIR34A MIR335 MIR30A MIR223 MIR222 MIR221
49 type 2 diabetes mellitus 28.8 MIR34A MIR335 MIR30A MIR223 MIR221 MIR214
50 muscular dystrophy, duchenne type 28.8 MIR34A MIR335 MIR30A MIR299 MIR222 MIR221

Comorbidity relations with Dermatomyositis via Phenotypic Disease Network (PDN):


Acute Cystitis Polymyositis

Graphical network of the top 20 diseases related to Dermatomyositis:



Diseases related to Dermatomyositis

Symptoms & Phenotypes for Dermatomyositis

Human phenotypes related to Dermatomyositis:

58 30 (show all 50)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 autoimmunity 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002960
2 emg abnormality 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0003457
3 myalgia 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0003326
4 abnormal eyelid morphology 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000492
5 periorbital edema 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0100539
6 erythema 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0010783
7 proximal muscle weakness 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0003701
8 inflammatory myopathy 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0009071
9 hypotonia 58 30 Frequent (33%) Frequent (79-30%)
HP:0001252
10 respiratory insufficiency 58 30 Frequent (33%) Frequent (79-30%)
HP:0002093
11 arthritis 58 30 Frequent (33%) Frequent (79-30%)
HP:0001369
12 recurrent respiratory infections 58 30 Frequent (33%) Frequent (79-30%)
HP:0002205
13 fatigue 58 30 Frequent (33%) Frequent (79-30%)
HP:0012378
14 acrocyanosis 58 30 Frequent (33%) Frequent (79-30%)
HP:0001063
15 abnormality of the nail 58 30 Frequent (33%) Frequent (79-30%)
HP:0001597
16 dry skin 58 30 Frequent (33%) Frequent (79-30%)
HP:0000958
17 skin ulcer 58 30 Frequent (33%) Frequent (79-30%)
HP:0200042
18 arthralgia 58 30 Frequent (33%) Frequent (79-30%)
HP:0002829
19 weight loss 58 30 Frequent (33%) Frequent (79-30%)
HP:0001824
20 abnormal hair quantity 58 30 Frequent (33%) Frequent (79-30%)
HP:0011362
21 papule 58 30 Frequent (33%) Frequent (79-30%)
HP:0200034
22 pruritus 58 30 Frequent (33%) Frequent (79-30%)
HP:0000989
23 chondrocalcinosis 58 30 Frequent (33%) Frequent (79-30%)
HP:0000934
24 pulmonary fibrosis 58 30 Frequent (33%) Frequent (79-30%)
HP:0002206
25 diffuse reticular or finely nodular infiltrations 58 30 Frequent (33%) Frequent (79-30%)
HP:0002207
26 dysphonia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001618
27 feeding difficulties in infancy 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0008872
28 fever 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001945
29 myocardial infarction 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001658
30 telangiectasia of the skin 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0100585
31 aplasia/hypoplasia of the skin 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0008065
32 lymphoma 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002665
33 cellulitis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0100658
34 pericarditis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001701
35 myocarditis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0012819
36 vasculitis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002633
37 cutaneous photosensitivity 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000992
38 pulmonary arterial hypertension 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002092
39 breast carcinoma 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0003002
40 gangrene 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0100758
41 sinus tachycardia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0011703
42 lung adenocarcinoma 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0030078
43 gastrointestinal stroma tumor 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0100723
44 abnormal eosinophil morphology 30 Occasional (7.5%) HP:0001879
45 arrhythmia 58 Occasional (29-5%)
46 neoplasm 58 Occasional (29-5%)
47 abnormality of the voice 58 Occasional (29-5%)
48 abnormality of eosinophils 58 Occasional (29-5%)
49 interstitial pulmonary abnormality 58 Frequent (79-30%)
50 edema 58 Very frequent (99-80%)

UMLS symptoms related to Dermatomyositis:


pruritus; exanthema

Drugs & Therapeutics for Dermatomyositis

Drugs for Dermatomyositis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 124)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pirfenidone Approved, Investigational Phase 4 53179-13-8 40632
2
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
3
Tofacitinib Approved, Investigational Phase 4 477600-75-2 9926791
4
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
5 Anti-Inflammatory Agents, Non-Steroidal Phase 4
6 Melanocyte-Stimulating Hormones Phase 4
7 Adrenocorticotropic Hormone Phase 4
8
beta-Endorphin Phase 4
9 Immunoglobulins Phase 4
10 Antibodies Phase 4
11 Protein Kinase Inhibitors Phase 4
12 Calcineurin Inhibitors Phase 4
13 Janus Kinase Inhibitors Phase 4
14
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
15
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
16
Prednisolone Approved, Vet_approved Phase 3 50-24-8 4894 5755
17
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5 1875
18
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 4159 6741
19
Dronabinol Approved, Illicit Phase 3 1972-08-3 16078
20
Benzocaine Approved, Investigational Phase 2, Phase 3 1994-09-7, 94-09-7 2337
21
Tannic acid Approved Phase 2, Phase 3 1401-55-4 16129878 16129778
22
Tacrolimus Approved, Investigational Phase 2, Phase 3 104987-11-3 6473866 445643
23
Azathioprine Approved Phase 3 446-86-6 2265
24
Ravulizumab Approved, Investigational Phase 2, Phase 3 1803171-55-2
25
Aldesleukin Approved Phase 3 110942-02-4
26
Levoleucovorin Approved, Experimental, Investigational Phase 2, Phase 3 68538-85-2, 58-05-9, 73951-54-9 149436 6006
27
Methotrexate Approved Phase 2, Phase 3 1959-05-2, 59-05-2 4112 126941
28
Abatacept Approved Phase 3 332348-12-6
29
Etanercept Approved, Investigational Phase 2, Phase 3 185243-69-0
30
Ustekinumab Approved, Investigational Phase 3 815610-63-0
31
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
32
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7 4897
33
PF-06700841 Investigational Phase 3 1883299-62-4 118878093
34 gamma-Globulins Phase 3
35 Rho(D) Immune Globulin Phase 3
36
Methylprednisolone Acetate Phase 3 584547
37 Psychotropic Drugs Phase 3
38 Hallucinogens Phase 3
39 Cyclosporins Phase 3
40 Interleukin 1 Receptor Antagonist Protein Phase 2, Phase 3
41 Pharmaceutical Solutions Phase 3
42 Complement System Proteins Phase 2, Phase 3
43 Immunoglobulin G Phase 3
44 Protective Agents Phase 2, Phase 3
45 Anti-Bacterial Agents Phase 2, Phase 3
46 Antidotes Phase 2, Phase 3
47 Calcium, Dietary Phase 2, Phase 3
48
Sodium thiosulfate Phase 2, Phase 3
49 Antitubercular Agents Phase 2, Phase 3
50 Antioxidants Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 105)
# Name Status NCT ID Phase Drugs
1 Randomized Controlled Trial of Pirfenidone in Patients With Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis Unknown status NCT02821689 Phase 4 Pirfenidone
2 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
3 Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis Completed NCT02245841 Phase 4 H.P. Acthar Gel
4 Abatacept for the Treatment of Refractory Juvenile Dermatomyositis Completed NCT02594735 Phase 4 Abatacept
5 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
6 The Efficacy and Safety of JAK Inhibitor in the Treatment of Anti-MDA5 Antibody-positive Dermatomyositis Patients Recruiting NCT04966884 Phase 4 JAK Inhibitor
7 Efficacy and Safety of Triple Therapy Based on Prognostic Risk Stratification in Patients With Anti-MDA5 Antibody-positive Dermatomyositis: a Multicenter, Prospective, Randomized Controlled Study Recruiting NCT05375435 Phase 4 triple therapy;dual-therapy
8 A Phase III, Randomized, Double-blind, Placebo Controlled, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Pirfenidone in Subjects With Dermatomyositis Interstitial Lung Disease (Dm-ILD) Unknown status NCT03857854 Phase 3 Pirfenidone;Placebos
9 Prospective, Double-blind, Randomized, Placebo-Controlled Phase III Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis ("ProDERM Study") Completed NCT02728752 Phase 3 Octagam 10%
10 A Prospective, Randomised, Assessor-blind, Multicenter Study of Efficacy and Safety of Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With Polymyositis and Dermatomyositis. Completed NCT00651040 Phase 3 Prednisone;Methotrexate
11 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis Completed NCT03813160 Phase 3 Lenabasum 20 mg;Lenabasum 5 mg;Placebo
12 An Open-label Clinical Trial of the Combination Treatment of Tacrolimus and Corticosteroid in Polymyositis/Dermatomyositis Patients With Interstitial Pneumonitis, With Comparison Against Corticosteroid-treated Historical Controls Completed NCT00504348 Phase 2, Phase 3 Tacrolimus
13 A Randomized, Double-blind, Controlled Clinical Study of GB-0998 for the Steroid-resistant Polymyositis and Dermatomyositis Completed NCT00335985 Phase 3 GB-0998;Placebo of GB-0998
14 Five-year Single-blind, Phase III Effectiveness Randomised Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis: Prednisone Versus Prednisone Plus Cyclosporine a Versus Prednisone Plus Methotrexate Completed NCT00323960 Phase 3 3 MPDN pulse + PDN;3 MPDN pulse + PDN + CSA;3 MPDN pulse + PDN + MTX
15 Anakinra in Patients With Refractory Idiopathic Inflammatory Myopathies Completed NCT01165008 Phase 2, Phase 3 Anakinra
16 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults With Dermatomyositis (DM) - The RECLAIIM Study Recruiting NCT04044690 Phase 3 human immunoglobulin G;Placebo
17 Baricitinib in Patients With Relapsing or naïve Dermatomyositis: a Multicenter Randomized Controlled Trial (BIRD) Recruiting NCT04972760 Phase 3 Baricitinib;Placebo
18 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Oral Brepocitinib in Adults With Dermatomyositis Recruiting NCT05437263 Phase 3 Brepocitinib;Placebo
19 A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Dermatomyositis Recruiting NCT04999020 Phase 2, Phase 3 Ravulizumab;Placebo
20 An Open-label Study of Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis Active, not recruiting NCT03267277 Phase 2, Phase 3 Sodium Thiosulfate
21 Therapeutic Effect of Interleukin-2 on Active Dermatomyositis: A Multicenter, Randomised, Double-blind, Placebo-controlled Trial Enrolling by invitation NCT05495321 Phase 3 Interleukin-2
22 Double-blind, Randomized, Placebo-Controlled Phase III Study Evaluating Efficacy and Safety of Subcutaneous Human Immunoglobulin (Octanorm) in Patients With Dermatomyositis (SCGAM-02) Terminated NCT03686969 Phase 3 Octanorm
23 Toward Improved Understanding of Pathogenesis and Treatment of Childhood Onset Dermatomyositis Terminated NCT00035958 Phase 2, Phase 3 Prednisone;Methotrexate;Etanercept
24 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments Terminated NCT03981744 Phase 3 Ustekinumab 6 mg/kg;Ustekinumab 90 mg;Placebo IV;Placebo SC
25 A Phase 3, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC With Standard Treatment Compared to Standard Treatment Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy (IIM) Terminated NCT02971683 Phase 3 Abatacept subcutaneous;Placebo
26 Basiliximab as a Treatment of Interstitial Pneumonia in Clinical Amyopathic Dermatomyositis Patients Unknown status NCT03192657 Phase 2 Basiliximab;Calcineurin Inhibitors;Steroids
27 Rituximab Therapy in Refractory Adult and Juvenile Idiopathic Inflammatory Myopathy (IIM) Completed NCT00106184 Phase 2 Rituximab;Placebo
28 A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis Completed NCT02612857 Phase 2 IMO-8400 Dose Group 1;IMO-8400 Dose Group 2;Placebo
29 Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis Completed NCT02043548 Phase 2 tocilizumab;placebo
30 Open Label Proof of Concept Study to Evaluate Efficacy and Safety of Adrenocorticotropic Hormone Gel in Refractory Dermatomyositis or Polymyositis Completed NCT01906372 Phase 2 Adrenocorticotropic Hormone Gel
31 A Randomized, Third-Party-Blind, Placebo-Controlled Pilot Study of the Effect of h5G1.1-mAb on Dermatomyositis Patients Completed NCT00005571 Phase 2 h5G1.1-mAb
32 A Phase 2 Randomized, Double-blind, Placebo-controlled, Crossover Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients With Active Polymyositis or Dermatomyositis Completed NCT04033926 Phase 2 KZR-616;Placebo
33 A Randomized, Double-Blind, Placebo-Controlled Trial of Infliximab in Patients With Dermatomyositis and Polymyositis Completed NCT00033891 Phase 2 Infliximab
34 Phase II Study of Prednisolone/Methylprednisolone Absorption in Children With Juvenile Dermatomyositis Completed NCT00004357 Phase 2 Methylprednisolone;Prednisolone
35 A Phase 2, Open Label Single Arm Study for Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis Completed NCT03529955 Phase 2 Apremilast 30mg
36 A Pilot Study of the Role of Methimazole in Patients With Polymyositis and Dermatomyositis Completed NCT00001421 Phase 2 methimazole
37 Novel Drug Delivery of Sodium Thiosulfate for Calcinosis Associated With Adult and Juvenile Dermatomyositis Completed NCT01572844 Phase 2 Sodium thiosulfate
38 Efficacy of an Individual Rehabilitation Program in Polymyositis and Dermatomyositis Completed NCT01415219 Phase 2
39 Abatacept Treatment in Polymyositis and Dermatomyositis Completed NCT01315938 Phase 2 Abatacept Active Treatment;Abatacept Delayed-Onset Treatment
40 The Efficacy of High-Dose Intravenous Immunoglobulin in Patients With Inflammatory Myopathies: A Three Month Randomized Trial With Option for Cross-Over Completed NCT00001261 Phase 2 Gamma Globulin
41 Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis Recruiting NCT05524311 Phase 2 Baricitinib
42 Subcutaneous Injection of Sodium Thiosulfate for Ectopic Calcifications or Ossifications. A Pilot Study Recruiting NCT03582800 Phase 2 STS
43 Booster Effects With Autoimmune Treatments in Patients With Poor Response to Initial COVID-19 Vaccine (ACV01) Recruiting NCT05000216 Phase 2 Continue IS (MMF or MPA);Continue IS (MTX);Withhold IS (MMF or MPA);Withhold IS (MTX);Withhold IS (B cell depletion therapy)
44 AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO INVESTIGATE THE SAFETY OF PF-06823859 ADMINISTERED TO ADULT PARTICIPANTS ≥18 AND ≤80 WITH ACTIVE DERMATOMYOSITIS. Active, not recruiting NCT05192200 Phase 2 Anti-Beta Interferon (PF-06823859)
45 A PHASE 2 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-06823859 IN ADULT SUBJECTS WITH DERMATOMYOSITIS Active, not recruiting NCT03181893 Phase 2 PF-06823859 low;Placebo Arm;PF-06823859 high
46 An Open-label Extension to the Phase 2 Randomized, Double-blind, Placebo-controlled, Crossover Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients With Active Polymyositis or Dermatomyositis Enrolling by invitation NCT04628936 Phase 2 KZR-616
47 A Prospective, Open, Dose-escalation, Multi-center, Phase 1/2a Trial to Evaluate the Safety, Tolerability and to Explore the Efficacy of PN-101 in Patients With Refractory Polymyositis or Dermatomyositis Enrolling by invitation NCT04976140 Phase 1, Phase 2
48 An Open-Label Pilot Study to Evaluate the Efficacy and Safety of Baricitinib in Subjects With Cutaneous Dermatomyositis Not yet recruiting NCT05361109 Phase 2 Baricitinib
49 A Double Blind, Randomized, Placebo-controlled Study to Evaluate, Safety, Tolerability, Efficacy and Preliminary Dose-response of BAF312 in Patients With Active Dermatomyositis (DM) Terminated NCT02029274 Phase 2 BAF312;Placebo
50 A Multi-centre, Double-blind, Placebo Controlled, Proof of Concept Study to Evaluate the Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis Terminated NCT01148810 Phase 2 BAF312;Placebo

Search NIH Clinical Center for Dermatomyositis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Immunoglobulins, Intravenous
Potassium aminobenzoate

Cochrane evidence based reviews: dermatomyositis

Genetic Tests for Dermatomyositis

Anatomical Context for Dermatomyositis

Organs/tissues related to Dermatomyositis:

FMA: Muscle, Skin Where A Skin Rash Is Often Seen Prior To The Onset Of Muscle Weakness
MalaCards : Skin, Lung, Bone, Breast, T Cells, Skeletal Muscle, Neutrophil

Publications for Dermatomyositis

Articles related to Dermatomyositis:

(show top 50) (show all 10172)
# Title Authors PMID Year
1
Distinctive patterns of microRNA expression in primary muscular disorders. 62 46
17942673 2007
2
Expression of TLR2, TLR4, and TLR9 in dermatomyositis and polymyositis. 53 62
19953283 2010
3
A dual role for HSP90 and HSP70 in the inflammatory myopathies: from muscle fiber protection to active invasion by macrophages. 53 62
19758187 2009
4
Th1 and Th17 balance in inflammatory myopathies: interaction with dendritic cells and possible link with response to high-dose immunoglobulins. 53 62
19303320 2009
5
An evaluation of the efficacy of the toe brachial index measuring vascular involvement in systemic sclerosis and other connective tissue diseases. 53 62
19796558 2009
6
Nonspecific interstitial pneumonia associated with collagen vascular disease: analysis of CT features to distinguish the various types. 53 62
19443969 2009
7
Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato/polymyositis. 53 62
18578962 2008
8
Inducible overexpression of wild-type prion protein in the muscles leads to a primary myopathy in transgenic mice. 53 62
17420473 2007
9
Immunolocalization of interleukin-1 receptors in the sarcolemma and nuclei of skeletal muscle in patients with idiopathic inflammatory myopathies. 53 62
17265504 2007
10
Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review. 53 62
17207162 2007
11
Signs of inflammation in both symptomatic and asymptomatic muscles from patients with polymyositis and dermatomyositis. 53 62
16831829 2006
12
MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: association with muscle involvement. 53 62
16859997 2006
13
Difference in adhesion molecule expression (ICAM-1 and VCAM-1) in juvenile and adult dermatomyositis, polymyositis and inclusion body myositis. 53 62
16431335 2006
14
Autoantibodies against the replication protein A complex in systemic lupus erythematosus and other autoimmune diseases. 53 62
16846524 2006
15
[Pravastatin-induced dermatomyositis]. 53 62
16154665 2005
16
Diagnostic significance of membrane attack complex and vitronectin in childhood dermatomyositis. 53 62
16159528 2005
17
Chemokine receptor CCR7 is expressed in muscle fibers in juvenile dermatomyositis. 53 62
15950936 2005
18
Tumor antigen markers for the detection of solid cancers in inflammatory myopathies. 53 62
15894686 2005
19
Changes of single fiber electromyography in patients with inflammatory myopathies. 53 62
15844301 2005
20
[A case of dermatomyositis associated with different types of cancers at intervals of six years]. 53 62
15678898 2004
21
Mitochondrial abnormalities in dermatomyositis: characteristic pattern of neuropathology. 53 62
15614615 2004
22
Dermatomyositis associated with Sjögren's syndrome: VEGF involvement in vasculitis. 53 62
15328883 2004
23
Immunolocalization of protectin (CD59) and macrophages in polymyositis and dermatomyositis. 53 62
15020079 2004
24
Immunohistochemical analysis of adhesion molecule expression on muscle biopsy specimens from patients with juvenile dermatomyositis. 53 62
15088312 2004
25
Anticyclic citrullinated peptide antibodies in patients with mixed connective tissue disease. 53 62
17143695 2004
26
Cytokines in juvenile dermatomyositis pathophysiology: potential and challenge. 53 62
14569197 2003
27
Expression of calcium-binding proteins MRP8 and MRP14 in inflammatory muscle diseases. 53 62
12937135 2003
28
Update on juvenile dermatomyositis: new advances in understanding its etiopathogenesis. 53 62
12960487 2003
29
Interleukin-17 increases the effects of IL-1 beta on muscle cells: arguments for the role of T cells in the pathogenesis of myositis. 53 62
12667656 2003
30
Relationship between utrophin and regenerating muscle fibers in duchenne muscular dystrophy. 53 62
12619170 2003
31
Clinical significance of serum surfactant protein D (SP-D) in patients with polymyositis/dermatomyositis: correlation with interstitial lung disease. 53 62
12421999 2002
32
Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. 53 62
12235211 2002
33
[A case of amyopathic dermatomyositis with systemic sclerosis sine scleroderma presenting abnormal vermiculation]. 53 62
12355862 2002
34
Overview of neuromuscular disorders affecting respiratory function. 53 62
16088611 2002
35
Increased plasma thrombospondin-1 (TSP-1) levels are associated with the TNF alpha-308A allele in children with juvenile dermatomyositis. 53 62
12173300 2002
36
Interleukin-1alpha expression in capillaries and major histocompatibility complex class I expression in type II muscle fibers from polymyositis and dermatomyositis patients: important pathogenic features independent of inflammatory cell clusters in muscle tissue. 53 62
11953983 2002
37
Increased expression of the normal cellular isoform of prion protein in inclusion-body myositis, inflammatory myopathies and denervation atrophy. 53 62
11303793 2001
38
Cardiac troponin and beta-type myosin heavy chain concentrations in patients with polymyositis or dermatomyositis. 53 62
11282091 2001
39
Autoantibodies to fibrillin 1 in systemic sclerosis: ethnic differences in antigen recognition and lack of correlation with specific clinical features or HLA alleles. 53 62
11083269 2000
40
Increased interleukin-17 production in patients with systemic sclerosis. 53 62
11083268 2000
41
Increased CD40 expression on muscle cells of polymyositis and dermatomyositis: role of CD40-CD40 ligand interaction in IL-6, IL-8, IL-15, and monocyte chemoattractant protein-1 production. 53 62
10843719 2000
42
Kinetics of anti-fibrillin-1 autoantibodies in MCTD and CREST syndrome. 53 62
10756089 2000
43
Abnormal IL-1 receptor antagonist production in patients with polymyositis and dermatomyositis. 53 62
10732829 2000
44
Increased expression of beta-chemokines in muscle of patients with inflammatory myopathies. 53 62
10749105 2000
45
Dermatomyositis with erosive arthropathy: association with the anti-PL-7 antibody. 53 62
10606385 1999
46
[Cytomegalovirus infection associated with immunosuppressive therapy in collagen vascular diseases]. 53 62
10614168 1999
47
[Amyopathic dermatomyositis with interstitial pneumonia: effective treatment with cyclophosphamide pulse therapy]. 53 62
10496106 1999
48
Costimulatory markers in muscle of patients with idiopathic inflammatory myopathies and in cultured muscle cells. 53 62
10444360 1999
49
[Expression of adhesion molecules in idiopathic inflammatory myopathies. Immunohistochemical study of 17 cases]. 53 62
10320905 1999
50
Dermatomyositis and drugs. 53 62
10599342 1999

Variations for Dermatomyositis

Expression for Dermatomyositis

Search GEO for disease gene expression data for Dermatomyositis.

Pathways for Dermatomyositis

GO Terms for Dermatomyositis

Cellular components related to Dermatomyositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.93 MIR335 MIR30A MIR223 MIR222 MIR221 MIR210
2 RISC complex GO:0016442 9.88 MIR130A MIR132 MIR146B MIR148A MIR148B MIR154
3 extracellular vesicle GO:1903561 9.56 MIR34A MIR30A MIR222 MIR221 MIR214 MIR21

Biological processes related to Dermatomyositis according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 10.01 MIR34A MIR214 MIR21 MIR155 MIR132
2 negative regulation of cell migration GO:0030336 9.93 MIR34A MIR335 MIR214 MIR21
3 positive regulation of protein kinase B signaling GO:0051897 9.88 MIR132 MIR21 MIR221 MIR222
4 positive regulation of angiogenesis GO:0045766 9.88 MIR130A MIR132 MIR199B MIR21 MIR210 MIR30A
5 negative regulation of angiogenesis GO:0016525 9.86 MIR34A MIR222 MIR214 MIR21
6 miRNA-mediated gene silencing GO:0035195 9.85 MIR130A MIR132 MIR146B MIR148A MIR148B MIR154
7 positive regulation of epithelial to mesenchymal transition GO:0010718 9.79 MIR222 MIR221 MIR21
8 positive regulation of G1/S transition of mitotic cell cycle GO:1900087 9.78 MIR222 MIR221 MIR214
9 positive regulation of blood vessel endothelial cell migration GO:0043536 9.77 MIR30A MIR221 MIR210
10 negative regulation of NIK/NF-kappaB signaling GO:1901223 9.75 MIR223 MIR21 MIR132
11 negative regulation of vascular associated smooth muscle cell proliferation GO:1904706 9.73 MIR362 MIR34A MIR223 MIR214
12 positive regulation of vascular endothelial cell proliferation GO:1905564 9.7 MIR21 MIR132 MIR130A
13 miRNA-mediated gene silencing by mRNA destabilization GO:0035279 9.67 MIR223 MIR214 MIR210 MIR130A
14 positive regulation of vascular associated smooth muscle cell proliferation GO:1904707 9.65 MIR222 MIR221 MIR214 MIR21 MIR130A
15 positive regulation of axon regeneration GO:0048680 9.64 MIR222 MIR221
16 negative regulation of cell adhesion molecule production GO:0060354 9.64 MIR222 MIR221
17 negative regulation by host of viral genome replication GO:0044828 9.63 MIR222 MIR221
18 positive regulation of connective tissue replacement GO:1905205 9.62 MIR34A MIR214
19 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.59 MIR210 MIR21
20 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.57 MIR222 MIR221
21 miRNA-mediated gene silencing by inhibition of translation GO:0035278 9.56 MIR132 MIR148A MIR148B MIR21 MIR210 MIR221
22 negative regulation of BMP secretion GO:2001285 9.55 MIR214 MIR210
23 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.55 MIR362 MIR34A MIR223 MIR214 MIR21
24 negative regulation of hematopoietic stem cell proliferation GO:1902034 9.54 MIR222 MIR221
25 positive regulation of vascular associated smooth muscle cell dedifferentiation GO:1905176 9.51 MIR221 MIR214
26 negative regulation of interleukin-21 production GO:0032705 9.5 MIR222 MIR221 MIR21
27 negative regulation of TRAIL-activated apoptotic signaling pathway GO:1903122 9.49 MIR222 MIR221
28 positive regulation of Schwann cell migration GO:1900149 9.48 MIR222 MIR221
29 positive regulation of Schwann cell proliferation involved in axon regeneration GO:1905046 9.46 MIR222 MIR221

Molecular functions related to Dermatomyositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.65 MIR34A MIR335 MIR30A MIR223 MIR214 MIR210
2 mRNA base-pairing translational repressor activity GO:1903231 9.6 MIR362 MIR34A MIR335 MIR30A MIR299 MIR223

Sources for Dermatomyositis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....